To evaluate the clinical efficiency , tolerance , and pharmacoeconomic parameters of treatment for mild community-acquired pneumonia ( CAP ) in patients with risk factors for ineffective treatment with levofloxacin ( Glevo ) versus original levofloxacin and standard pharmacotherapy regimens for mild pneumonia ( real practice ) .